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A randomized comparison of covered versus uncovered biliary metal stents during 
neoadjuvant therapy in pancreatic cancer 
 
Short Title: Biliary Metal Stents in Neoadjuvant Therapy 
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Abstract 
Background and Aims: Preoperative biliary drainage with self-expanding metal stents (SEMSs) 
brings liver function within acceptable range in preparation for neoadjuvant therapy (NATx) and 
provides relief of obstructive symptoms in patients with pancreatic cancer. We compared fully 
covered SEMSs (FCSEMSs) and uncovered SEMSs (UCSEMSs) for sustained biliary drainage 
before and during NATx.  
 
Methods: Patients with pancreatic cancer and planned NATx needing treatment of jaundice 
and/or cholestasis before pancreaticoduodenectomy were randomized to FCSEMS versus 
UCSEMS. Primary endpoint was sustained biliary drainage, defined as absence of 
reinterventions for biliary obstructive symptoms, and was assessed from SEMS placement until 
curative intent surgery (CIS) or 1 year.  
 
Results: The intent-to-treat population had 119 patients (59 FCSEMS, 60 UCSEMS). Sustained 
biliary drainage was equally successful with FCSEMS and UCSEMS (72.2% vs 72.9%, 
noninferiority P=0.01).  Reasons for FCSEMS and UCSEMS failure differed significantly 
between groups and included tumor ingrowth in 0 versus 16.7%, P<0.01, and stent migration in 
6.8% vs. 0, P=0.03, respectively. Serious adverse event rates related to stent placement were 
insignificantly different in both groups (23.7% (14/59) vs 20.0% (12/60), P=0.66), as were acute 
cholecystitis rates when gallbladder in situ (9.3% (4/43) vs 4.8% (2/42), P=0.68) for FCSEMSs 
and UCSEMSs, respectively. In our study, independent of stent type, predictors of 
reinterventions were 4 cm stent length and presence of gallbladder.   
 
Conclusion: FCSEMSs and UCSEMSs provide similar preoperative management of biliary 
obstruction in pancreatic cancer patients receiving NATx, but mechanisms of stent dysfunction 
depend on stent type, stent length, and presence of the gallbladder.   
 
Key Words: pancreatic cancer; biliary obstruction; fully covered self-expanding metal stents; 
uncovered self-expanding metal stents; neoadjuvant therapy; preoperative management. 
 
Clinical Trial Registration: ClinicalTrials.gov NCT02238847 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
Introduction 
In the United States, pancreatic cancer is the second most common digestive cancer and the 
fourth leading cause of cancer death, with a 5-year survival rate of only 6%.(1) Approximately 
70% of patients with pancreatic cancer present with biliary obstruction,(2) and those with 
borderline resectable, locally advanced, or even resectable tumors often undergo preoperative 
neoadjuvant therapy (NATx) to downsize the tumor, provide early treatment of micrometastases, 
and ultimately optimize post-operative survival.(3-7) Preoperative biliary drainage mainly aims  
to resolve jaundice and bring elevated liver function tests (LFTs)  within acceptable range so that 
NATx may be initiated, and maintain relief of biliary obstructive symptoms during NATx.(8, 9) 
The latter decreases the risk of inciting  an inflammatory cascade in severely jaundiced 
patients,(10) and reduces the risk of adverse events from inadequate drainage, such as 
cholangitis.(11) Without effective preoperative drainage, patients may experience interruption of 
the NATx and/or delayed surgery.  
Uncovered (UC) and fully covered (FC) self-expanding metal stents (SEMS) were shown to be 
superior to plastic stents for preoperative biliary drainage due to increased stent patency.(12-16) 
FCSEMSs were developed to prevent tissue ingrowth. Several meta-analyses assessed 
UCSEMSs versus FCSEMSs, and although most have shown no differences in stent patency or 
patient survival, conflicting results were reported for rates of SEMS migration, tumor ingrowth, 
tumor overgrowth, and acute cholecystitis.(17-22) Both FCSEMSs and UCSEMSs used in this 
study are cleared for palliative treatment of malignant biliary strictures and relief of biliary 
obstruction before surgery. The FCSEMS is also indicated for treatment of some benign biliary 
strictures. Thus, FCSEMS given their removable attribute, can offer on-label advantages in the 
setting of biliary strictures of indeterminate etiology. We sought to assess in a prospective 
randomized fashion whether this FCSEMS was noninferior to the UCSEMS for preoperative 
sustained biliary drainage in pancreatic cancer patients with planned NATx before curative intent 
pancreaticoduodenectomy. We deemed this study would lead to benefit in clinical practice if 
noninferiority of a FCSEMS was demonstrated. As such, if an FCSEMS was chosen because a 
biliary stricture was indeterminate, a subsequent diagnosis of underlying malignancy should not 
entail FCSEMS exchange for an UCSEMS (because of concern for stent migration or 
development of cystic duct obstruction and cholecystitis). Although the study was not powered 
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to compare the rate of incidence of adverse events that are particularly feared in this 
immunosuppressed population, we documented adverse event rates carefully to rule out major 
differences between FCSEMS and UCSEMS groups.    
 
Methods 
Design 
In this international, prospective, multicenter trial (ClinicalTrials.gov NCT02238847), we 
randomized patients in a 1:1 ratio to preoperative biliary drainage with a FCSEMS versus 
UCSEMS (WallFlex Biliary RX Fully Covered and Uncovered Stent, Boston Scientific, 
Marlborough, Mass). Block randomization was performed via an online database accessed on 
site at the start of the procedure. Randomization was stratified by study site. At each site 
concealed envelopes were used as the back-up randomization system.   
Each participating institution’s Ethics Committee/Institutional Review Board approved the study 
and each patient gave written informed consent. All authors had access to the study data and 
reviewed and approved the final manuscript. 
The study stent system consists of a flexible delivery system preloaded with a radiopaque SEMS 
with flared ends. The FCSEMS is covered with a Permalume Coating (translucent silicone 
polymer) and has a retrieval loop for removal, neither features being contained in the UCSEMS. 
Selection of stent length and diameter were at the discretion of the Investigator.     
Patients and Procedures 
Patients with pancreatic cancer scheduled for NATx and needing preoperative biliary drainage 
before curative intent surgery (CIS) were screened for study eligibility. The location of the 
biliary stricture had to allow for the proximal end of the SEMS to be positioned at least 2 cm 
below the hilum to assure enough not previously stented bile duct for dissection and anastomosis 
during surgery. Patients were treated with NATx per local standard of medical oncology. 
Patients who proceeded to CIS were followed for 30 days post-surgery and their survival status 
was checked at 1 year. Patients who did not reach CIS proceeded to nonoperative, palliative care 
and were followed to 1 year after biliary SEMS placement.  
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Endpoints 
The primary endpoint was sustained biliary drainage, defined as absence of reinterventions for 
the management of biliary obstructive symptoms, assessed from SEMS placement until CIS 
when applicable or to one year after SEMS placement otherwise.    
Secondary endpoints included technical success defined as ability to deploy the stent in a 
satisfactory position across the stricture, ability to complete NATx as intended without stent-
related interruptions of NATx and without biliary reintervention, subjective impression of the 
surgeon that the presence of a SEMS may have impacted the surgical procedure, and serious 
adverse events (SAEs) related to the stent and/or stent placement procedure, up to 30 days after 
surgery where applicable or 1 year after stent placement for patients not undergoing surgery. 
Adverse events (AEs) were predefined as detailed in Appendix 1. Also assessed were mortality 
at one year after randomization and incidence of stent migration, stent occlusion due to tumor 
ingrowth, and acute cholecystitis as causes for reintervention, and improvement of liver function 
tests (LFTs) until surgery for patients undergoing surgery and until 1 year after stent placement 
for patients not undergoing surgery. 
Statistical Methods 
Statistical testing was performed to determine if the rate of attaining sustained biliary drainage 
when using the FCSEMS was noninferior to the rate when using the UCSEMS. A noninferiority 
design was selected because preoperative biliary drainage was first described using UCSEMS, 
but there have been no RCTs to establish if FCSEMS are, in fact, noninferior. This question is 
relevant because there were reports that FCSEMS have a higher risk of stent migration and of 
causing acute cholecystitis when the cystic duct confluence is covered by the FCSEMS, whereas 
it was also reported that UCS MS are associated with risk of occlusion due to tumor ingrowth. 
A meta-analysis of 9 pertinent articles representing 377 patients,(13, 15, 23-29) yielded a success 
rate estimate of 84.6% (95% confidence interval [CI], 80.5%-87.9%). Assuming the success rate 
of each arm was 80.5%, a sample size of 102 patients would provide 80% power to reject the 
null hypothesis that FCSEMSs are inferior to UCSEMSs, using a noninferiority margin of 20% 
and an exact noninferiority test with significance level of ≤0.05. Allowing for attrition, 
enrollment was capped at 120 patients. The 20% noninferiority margin was chosen to support a 
practical study size while still able to identify major differences in performance if this were the 
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case.  Although this margin may seem high, if FCSEMS were worse than UCSEMS by more 
than approximately 7% in this trial with 120 patients, the hypothesis would fail to be proven.  
Analyses were performed on all randomized patients according to the intention-to-treat (ITT) and 
per protocol (PP) principles.(30) The ITT group included all randomized patients. The PP group 
included all patients who were treated per protocol and had no major protocol deviations per 
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use guidelines. Patients eligible for primary endpoint analysis within the ITT analysis 
excluded those who died, withdrew consent, or were lost to follow-up before CIS or 1 year as 
applicable.   
Continuous baseline characteristics are presented as median with interquartile range (IQR) and 
compared between groups using the Wilcoxon rank-sum test. Categorical characteristics are 
presented as counts and percentages and compared between groups using the Fisher exact test, 
with corresponding Clopper-Pearson 95% CIs, where applicable. Kaplan-Meier estimates of 
endpoint events were calculated for each treatment group and tested using the log-rank test with 
Greenwood’s 95% CIs, where applicable.   
Univariate and multivariate analyses were performed to assess the effect on the primary endpoint 
of randomization group, age, gender, baseline bilirubin, alkaline phosphate, weight, and 
Karnofsky score,(31) stent length 4 cm, tumor location, tumor size, tumor stage, and whether 
chemotherapy included Gemcitabine using Cox proportional hazards regression. Stepwise 
selection was performed to build the multivariate model, with entry and exit set at P>0.1, and 
randomized group was forced to stay in model regardless of P value. SAS version 9.4 and 
StatXact version 11 were used for all analyses. P<0.05 was considered significant for all 
analyses. 
Results 
Study Population 
Patients were enrolled between March 2015 and April 2017 at 9 institutions in Belgium (1), 
Canada (1), Italy (1), Japan (1), Korea (1), United States (4). Of 136 screened patients, 17 were 
not eligible for randomization, and 119 were randomized (59 to FCSEMS, 60 to UCSEMS) 
comprising the ITT cohort. Of these, 113 patients were eligible for primary endpoint analysis. 
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Two patients, one in each arm, received the stent type not attributed by randomization; thus 111 
patients comprised the PP cohort. Six patients were not evaluable for primary endpoint analysis.  
One patient withdrew consent immediately after uneventful placement of a FCSEMS. Two 
patients died before potential CIS, one on day 40 of progression of pancreatic cancer after 
UCSEMS placement, and one on day 44 from iatrogenic causes related to chemotherapy without 
stent-related adverse events with confirmed FCSEMS patency on CT and ERCP. Three patients 
were lost to follow-up after placement of a FCSEMS on day 14 day 38, and day 283 without 
stent-related adverse events and with improved LFTs at last visits.   
Of the 113 patients eligible for primary endpoint analysis, 51 (45.1%) patients underwent CIS 
and 62 (54.9%) patients did not (Figure 1). 
Median follow-up for ITT primary endpoint analysis was 206 days (IQR 126-327) overall, 207 
days (IQR 136-336) in the FCSEMS group, and 197 days (IQR 121-320) in the UCSEMS group 
(P=0.58).  
There were no significant differences in baseline characteristics between groups (Table 1) except 
for the Karnofsky score. Six patients had a low Karnofsky score of 50 or 60, 5 in the UCSEMS 
and one in the FCSEMS group. Tissue diagnosis was made by EUS fine-needle aspiration or 
biopsy (EUS-FNA/FNB) in the majority (111/119, 93.3%) and ductal biopsy and/or brushing in 
a few patients (8/119, 6.7%). All patients had pancreatic adenocarcinoma, more than 30% stage 
IIA and approximately 25% stage IIB. 
Stents and Technical Success 
Technical success of stent placement was 99.2%, resulting in 120 SEMS placed in 119 patients. 
One patient failed technical success of FCSEMS placement, positioned too far into the bile duct, 
but with its proximal end still below the hilum. Intraprocedural repositioning was not possible 
and a second FCSEMS was place inside the first one in a transpapillary position. The patient did 
not undergo CIS and was followed to 1 year without SEMS-related adverse events or 
reinterventions. 
There was no difference in size of stents used between groups (P=0.52). The great majority (115 
(96.6%)) were 10 mm in diameter. SEMS length was 6 cm in 85 (71.4%) and 4 cm in 32 (26.9%) 
(Table 1). A 4 cm stent length was selected in 14 of 32 (43.8%) FCSEMS and 18 of 32 (56.2%) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8
UCSEMS (P=0.50); thus, randomization did not significantly impact the decision to select a 4-
cm stent.  However, 30 of 32 (93.8%) 4-cm-length stents were selected in significantly more 
patients with gallbladder in situ compared with 2 of 32 (6.2%) for patients with a prior 
cholecystectomy (P<0.01).   
Sustained biliary drainage - Primary Endpoint 
Sustained biliary drainage assessed in 113 patients in the primary endpoint ITT cohort was 
reached in 72.2% (39/54) of patients with FCSEMS versus 72.9% (43/59) of patients with 
UCSEMS (P=0.01) as tested to the noninferiority margin of 20% (Table 2), also demonstrated 
by the 95% upper 1-sided CI limit of 14.8%. The 95% CI of difference also did not include the 
20% margin and was 0.7% (-16.0% to 17.5%).  
A tipping point sensitivity analysis was conducted to assess the effect of missing data in the 
FCSEMS test arm by counting them as  endpoint failures and eliminating the patient who 
withdrew consent on Day 0. In this analysis, successful decompression would have been 67.2% 
(39/58) in the FCSEMS versus 72.9% (43/59) in the UCSEMS group (P=0.05) as tested to the 
pre-study noninferiority margin of 20%, thus still proving  noninferiority.   
In the PP cohort sustained biliary drainage was attained in 71.7% (38/53) in the FCSEMS and in 
72.4% (42/58) in the UCSEMS group (P=0.01) as tested to the 20% noninferiority margin.  
Likewise, FCSEMS was noninferior to UCSEMS in the analysis of 51 patients eligible for the 
primary endpoint who underwent CIS (83.3% vs. 81.5%, noninferiority P=0.03). For the 62 
patients who did not undergo CIS and were followed for 1 year, there was a nonsignificant 
difference (63.3% vs 65.6%, noninferiority P=0.09).  
The Kaplan-Meier analysis of ITT patients, in which all 119 patients contribute until the time of 
failure, death, loss to follow-up, or withdrawal of consent, demonstrated that sustained biliary 
drainage at 6 months after randomization had a probability of 77.5% (95% CI, 65.3%-89.7%) for 
the FCSEMS group and 80.5% (95% CI, 69.3%-91.8%) in the UCSEMS group, and at 1 year 
had a probability of 61.0% (95% CI, 43.4%-78.7%) in the FCSEMS group versus 51.4% (95% 
CI, 28.2%-74.6%) in the UCSEMS group (P=0.97). In the subgroup of patients that underwent 
CIS, a Kaplan-Meier analysis of biliary decompression showed success at 6 months in 83.3% 
(95% CI, 68.4%-98.2%) in the FCSEMS group and in 84.1% (95% CI, 69.8%-98.4%) in the 
UCSEMS group. In the subgroup of patients that did not undergo CIS, the same analysis showed 
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success in 74.9% (95% CI, 58.7%-91.2%) in the FCSEMS group and in 78.9% (95% CI, 63.7%-
94.2%) in the UCSEMS group. The Kaplan-Meier analyses are shown in Figure 2 for the overall 
ITT cohort, and in Supplementary Figures 1 and 2 respectively for the subset of patients who 
underwent and did not undergo CIS.  
Mean bilirubin levels in the FCSEMS and UCSEMS groups responded from elevated levels 
before stent placement to rapid normalization maintained after stent placement until the end of 
follow-up, with a similar time response in both groups, as shown in Supplementary Figure 3. 
Neoadjuvant Therapy and Curative Intent Surgery 
No significant differences were observed between the FCSEMS and UCSEMS groups as it 
pertains to NATx and CIS (Table 2). 
Thirteen patients transitioned to palliative management (7) and died while on study or received 
CIS (6) between day 8 and day 63 after SEMS placement before the planned NATx was 
initiated.        
The rate of patients who completed NATx with delays with recurrent biliary obstruction 
requiring reintervention was similar in the FCSEMS and UCSEMS groups (P=0.99). 
The rate of patients undergoing CIS was 51 of 113 (45.1%) overall, and insignificantly different 
between groups (P=0.85). The median time to CIS was 110 days, also insignificantly different 
between groups.    
The empiric impression of the surgeon that the presence of a SEMS may have impacted the 
surgical procedure was similar in the FCSEMS and UCSEMS group (P=0.99) and did not appear 
to be related to stent length. 
Adverse events and reinterventions 
Overall procedure or SEMS-related SAEs occurred in 23.7% (14/59) in the FCSEMS versus 
20.0% (12/60) in the UCSEMS group (P=0.66) (Table 2). Of these 26 related SAEs, 24 resulted 
in a reintervention. In addition, 7 non-serious AEs resulted in a reintervention. Thus in total there 
were 31 reinterventions that are listed, including  the cause for the reintervention  and the type of 
reintervention in Supplementary Table 1.  
For 23 cases of cholangitis and/or biliary obstructive symptoms, the reported causes were 10 
UCSEMS ingrowth, 3 FCSEMS and 2 UCSEMS occlusion by sludge or necrotic debris, 4 
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FCSEMS migration, 1 FCSEMS and 1 UCSEMS overgrowth, 1 UCSEMS kinking, and 1 
FCSEMS had no observed SEMS occlusion or migration. For 6 cases of acute cholecystitis, the 
presumed cause was cystic duct confluence occlusion by the UCSEMS (2) or FCSEMS (4).    
Reinterventions for 10 UCSEMS ingrowth cases were SEMS-in-SEMS placement (8), 
percutaneous transhepatic biliary drainage (1), or biliary radiofrequency ablation (1). For the 6 
cases of acute cholecystitis, the associated reintervention was placement of a percutaneous 
cholecystostomy tube (4), exchange of the FCSEMS by an UCSEMS (1) or cholecystectomy (1). 
All 5 cases of FCSEMS migration underwent FCSEMS exchange for another stent. Among the 5 
cases of SEMS occlusion by sludge or necrotic debris, FCSEMS were removed and exchanged 
for another stent (4) or sludge was simply removed from an UCSEMS (1). The case of a 
gastrointestinal bleed was reported as most likely caused by partial migration over two-thirds of 
the length of the FCSEMS into the duodenum. The blood clot was left in place and the FCSEMS 
was removed and exchanged for an UCSEMS 1 month later.       
Comparing the FCSEMS and UCSEMS groups, there were significant differences in reasons for 
SEMS failure between groups (Figure 3), notably tumor ingrowth at 0% and 16.7% (P<0.01), 
and stent migration in 6.8% and 0% (P=0.03), respectively. Incidence of acute cholecystitis was 
insignificantly different between FCSEMS and UCSEMS groups, namely respectively 9.3% 
(95% CI, 2.6% - 22.1%) and 4.8% (95% CI, 2.6% - 14.7%) with a difference of 4.5% (95% CI, 
8.1% - 18.2%; P=0.68). One case of acute cholecystitis occurred on day 53 after FCSEMS 
placement and was associated with proximal FCSEMS migration.  
A Kaplan-Meier analysis of survival to 1 year shows no difference between FCSEMS group 
60.2% versus 56.8% in the UCSEMS group (P=0.57; Figure 4).  
Predictors of Sustained Biliary Drainage 
Significant predictors of failure to attain sustained biliary drainage included use of a stent with a 
length of 4 cm (as opposed to 6 or 8 cm) and if the gallbladder was in situ. Univariate analysis 
showed a hazard ratio [HR] 2.9 (95% CI, 1.4-6.0; P<0.01) if the patient had a 4 cm stent and a 
HR of 8.6 (95% CI, 1.6-45.7; P=0.01) if the gallbladder was present. In a multivariate analysis, 4 
cm stent length had a HR of 2.1 (95% CI, 1.0-4.3; P=0.05) and gallbladder in situ had a HR of 
6.9 (95% CI, 1.3-37.8; P=0.03; Figure 5).  
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Discussion 
This prospective multinational trial enrolled patients scheduled for NATx before CIS. All 
patients had pancreatic adenocarcinoma, confirmed by EUS FNA/FNB, ductal biopsy or 
brushing before enrollment in this study. All but 6 patients had a Karnofsky score of 70 or better.  
Patients were randomized to biliary decompression using a FCSEMS or an UCSEMS. FCSEMSs 
were shown to be noninferior to UCSEMSs for sustained biliary drainage on an ITT basis until 
CIS or to 1 year (72.2% vs. 72.9%, noninferiority P=0.01). A Kaplan-Meier analysis at 1 year 
after randomization confirms insignificant differences in sustained biliary drainage and shows 
similar times to reintervention when using FCSEMSs or UCSEMSs.  
Concerns have been raised about tissue ingrowth requiring reintervention when using 
UCSEMSs, and of migration and acute cholecystitis when using FCSEMSs(32), either of which 
can guide stent type choice by the endoscopist. Of 31 patients experiencing SEMS failure 
requiring reintervention before CIS or before 1 year in patients who do not undergo CIS there 
were significant differences in reasons for SEMS failure between groups. Tumor ingrowth 
requiring intervention was significantly more likely in the UCSEMS than in the FCSEMS group 
(P<0.01). For stent migration the opposite was true (P=0.03). Acute cholecystitis had a 
nonsignificant tendency to occur more frequently when using FCSEMSs (P=0.68).  
Improper stent functionality causing delays or noncompletion of chemotherapy were not 
different for FCSEMS and UCSEMS. There was also no difference between the FCSEMS versus 
UCSEMS groups in time to CIS (114 vs 106.5 days, P=0.94). This establishes that the UCSEMS 
and FCSEMS choices are insignificantly different in providing proper biliary drainage during 
NATx.   
In our study, the only significant predictors of failure to decompress biliary obstruction were 
SEMS of 4 cm length compared to 6 cm and 8 cm length and the presence of a gallbladder. 
Increased risk of failure occurred with a multivariate HR of 2.1 for SEMS of 4cm length 
compared to 6 cm and 8 cm length, and HR of 6.9 for patients with gallbladder in situ. It is 
noteworthy that selection of the 4 cm stent length was significantly more common among 
patients with gallbladder in situ compared to patients with a prior cholecystectomy (P<0.01).   
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In a recent retrospective cohort study with 645 patients, covered SEMSs (CSEMSs) and 
UCSEMSs had similar rates of clinical success in relief of bile duct obstruction and patency 
duration; however, among those with gallbladder in situ, CSEMS use was associated with 
increased acute cholecystitis; and in multivariable analysis, CSEMS use was associated with 
increased migration.(32) A retrospective series from Korea published in 2006 (33) concluded 
that acute cholecystitis occurred in 15 of 155 (9.7%) patients receiving SEMS for management 
of malignant biliary obstruction and was more likely when the tumor involved the cystic duct 
confluence. Also in 2006 (34) a Japanese retrospective series in 246 patients with unresectable 
distal malignant bile duct strictures receiving 171 CSEMSs and 75 UCSEMSs, 13 (5.3%) of 
patients developed acute cholecystitis, confirming association with tumor involvement at the 
cystic duct orifice, but not associated with CSEMS or UCSEMS type. More recently, in 2014, 
the same group in Japan (35) analyzed risk factors for CSEMS migration in a retrospective series 
of 290 patients and concluded that CSEMS migration occurred in 15.2%, associated with low 
radial force of the CSEMS, administration of chemotherapy, and duodenal tumoral involvement.         
Given comparable success rates of preoperative biliary decompression before and during NATx 
in pancreatic cancer patients and given that the price of the FCSEMS is higher than that of 
UCSEMSs in several markets, the removable aspect of the FCSEMS should be emphasized in 
settings of uncertain diagnosis and uncertain patient management plan. When cancer is not 
proven, FCSEMS placement can prevent, for example in autoimmune pancreatitis, the potential 
disaster of having placed an UCSEMS in a benign biliary stricture. If a FCSEMS was placed in 
the case of indeterminate biliary strictures and malignancy is subsequently confirmed, exchange 
of the FCSEMS for an UCSEMS is not warranted given findings of our study.    
There are several limitations to this study. Firstly, the study was fairly small, thus conclusions 
could be drawn from the primary endpoint, but analyses pertaining to different site-by-site 
medical oncology treatment regimens were not possible. Secondly, 2 patients, 1 per group, were 
not treated as randomized. Fortunately, a sensitivity analysis of this discrepancy between the ITT 
and PP analyses confirmed that this had no effect on the primary endpoint analysis. Last, this 
study was sponsored by the manufacturer of the UCSEMS and FCSEMS used in the study. An 
effort was made to mitigate unwanted bias by assuring data sharing and strong collaboration and 
oversight by the investigators throughout the study, from protocol development through data 
analyses and manuscript writing and review. Key representatives of the manufacturer 
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participated in these processes and hence are featured in the author list. Although this study was 
supported by the manufacturer of the SEMS used in this study, the Wallflex Biliary UCSEMS 
and FCSEMS are the only ones marketed in the United States and cleared by the FDA for relief 
of malignant biliary obstruction before surgery. 
In conclusion, this international randomized study demonstrated noninferiority of FCSEMS 
compared to UCSEMS for preoperative management of biliary obstruction in pancreatic cancer 
patients in the setting of NATx. Mechanisms of stent dysfunction depended on stent 
type―FCSEMS or UCSEMS―and attaining sustained biliary drainage depended on stent length 
and presence of gallbladder.  
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Tables and Figures 
Figure 1. Patient Flowchart. 
Abbreviations: CIS, curative intent surgery; FCSEMS, fully-covered, self-expanding metal stents; ITT, 
intention-to-treat; UCSEMS, uncovered, self-expanding metal stents. Enrollment cap was N=120 patients, but 
one patient was removed from the ITT cohort because of treatment with a SEMS before randomization. 
*Deaths due to disease progression/neoadjuvant therapy. 
 
Figure 2. Kaplan-Meier analysis of primary endpoint in the intention-to-treat analysis set. 
Kaplan-Meier curves are shown for the primary endpoint, namely sustained biliary drainage, 
according to randomized treatment arm in an ITT analysis with intended follow-up to CIS where 
applicable, or to 1 year otherwise. Sustained biliary drainage occurred in 61.0% of patients with 
FCSEMS versus 51.4% of patients with UCSEMS at 1 year (P=0.84) in an analysis of all N=119 
patients.   Abbreviations: CI, confidence interval; DBO, sustained biliary drainage; FC, fully-covered; UC, 
uncovered. 
Figure 3. Principal reasons for reintervention during the index procedure by randomized 
treatment group. Abbreviations: FCSEMS, fully covered self-expanding metal stents; UCSEMS, uncovered 
self-expanding metal stents. 
 
Figure 4. Kaplan-Meier Analysis of Survival to 1 Year. 
Kaplan-Meier curves are shown for survival to 1 year according to randomized treatment arm. 
60.2% of patients in FCSEMS group versus 56.8% of patients with UCSEMS at 1 year (P=0.57). 
Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered. 
Figure 5. Predictors of failure to attain sustained biliary drainage. Univariate and multivariate 
analysis of failure to attain sustained biliary drainage. Abbreviations: SEMS, self-expanding metal 
stent. 
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Table 1. Baseline characteristics. 
Baseline characteristics are presented for the intention-to-treat cohort. 
Patient characteristics*  
FCSEMSs 
N=59 
UCSEMSs 
N=60 P value 
Age 67.0 (IQR 58.0-71.0) 65.0 (IQR 58.5-73.0) 0.89 
Male 55.9% (33/59) 55.0% (33/60) 0.99 
Weight (kg) 77.7 (IQR 62.3-87) 78.4 (IQR 65.1-90.4) 0.47 
Gallbladder in Situ 72.9% (43/59) 70%% (42/60) 0.84 
Karnofsky Score 90.0 (IQR 80.0-100.0)  80.0 (IQR 80.0-90.0) 0.03 
    
Tumor characteristics    
Tumor Size, cm 3.1±1.4 (59) 2.9±50.9 (60) 0.93 
Tumor Stage   0.82 
  IA – T1 NO MO 11.9% (7/59) 5.0% (3/60)  
  IB – T2 NO MO 8.5% (5/59) 10.0% (6/60)  
  IIA – T3 NO MO 32.2% (19/59) 40.0% (24/60)  
  IIB – T1 N1 MO T2 N1 MO T3 N1 MO 25.4% (15/59) 25.0% (15/60)  
  III – T4 Any N M0 8.5% (5/59) 8.3% (5/60)  
  Unknown 13.6% (8/59) 11.7% (7/60)  
 
   
Procedure characteristics    
Technical Success 98.3% (58/59) 100% (60/60) 0.50 
Biliary sphincterotomy 91.5% (54/59) 93.3% (56/60) 0.74 
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Prophylactic antibiotics 47.5% (28/59) 46.7% (28/60) 0.99 
Stent Sizes   0.52 
  8 mm x 4 cm 0% (0/59) 3.3% (2/60)  
  8 mm x 6 cm 1.7% (1/59) 0% (0/60)  
  8 mm x 8 cm 1.7% (1/59) 0% (0/60)  
  10 mm x 4 cm 23.7% (14/59) 26.7% (16/60)  
  10 mm x 6 cm 72.9% (43/59) 68.3% (41/60)  
  10 mm x 8 cm 0% (0/59) 1.7% (1/60)  
Characteristics are presented as % (n) and medians with interquartile ranges (IQR).  
Abbreviations: IQR, interquartile range; FC-SEMSs, fully-covered self-expanding metal stents; UC-SEMSs, 
uncovered self-expanding metal stents. 
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Table 2. Key Outcomes. 
Effectiveness Outcome  FCSEMSs UCSEMSs P value 
Sustained biliary drainage (Primary Endpoint) 72.2% (39/54) 72.9% (43/59)   0.01* 
Neoadjuvant Therapy Not Completed** 18.2% (10/55) 28.8% (15/52) 0.25 
Neoadjuvant Therapy Completed with Delay 16.4% (9/55) 11.5% (6/52) 0.58 
With recurrent biliary obstruction requiring 
reintervention 
3.6% (2/55) 1.9% (1/52) 0.99 
Patients with CIS 43.6% (24/55) 45.8% (27/59) 0.58 
  SEMS Impacted surgical procedure  13.0% (3/24) 15.4% (4/27) 0.99 
  Median Time to CIS (N=50) 
114.0 
(IQR 90.5-168.5) 
106.5 
(IQR 83.0-211.0) 
0.94 
Procedure-Related/Stent-Related Serious AEs FCSEMS UCSEMS P Value 
Acute cholecystitis 9.3% (4/43) 4.8% (2/42) 0.68 
Acute pancreatitis*** 1.7% (1/59) 0% (0/60) 0.50 
Cholangitis 15.3% (9/59) 13.3% (8/60) 0.80 
Gastrointestinal hemorrhage 1.7% (1/59) 0% (0/60) 0.50 
Abdominal pain 1.7% (1/59) 3.3% (2/60) 0.99 
CBD Obstruction or Abnormal LFTs 3.4% (2/59) 1.7% (1/60) 0.62 
Liver abscess 0% (0/59) 1.7% (1/60) 0.99 
Total 23.7% (14/59) 20.0% (12/60) 0.66 
Abbreviations: FC-SEMSs, fully-covered self-expanding metal stents; UC-SEMSs, uncovered self-expanding 
metal stents. 
*Noninferiority P value. 
**None with recurrent biliary obstruction requiring reintervention 
***Excludes reports of mild acute pancreatitis. 
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Supplemental Appendix 
 
Covered and uncovered biliary metal stents provide similar relief of biliary obstruction 
during neoadjuvant therapy in pancreatic cancer: a randomized trial 
 
Short Title: Biliary metal stents in neoadjuvant therapy 
 
 
 
Dong Wan Seo1; Stuart Sherman2; Kulwinder S. Dua3; Adam Slivka4; Andre Roy5; Guido 
Costamagna6; Jacques Deviere7; Joyce Peetermans8; Matthew Rousseau8; Yousuke Nakai9; 
Hiroyuki Isayama9*, and Richard Kozarek10 for the “Biliary SEMS during neoadjuvant therapy 
study group” 
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Appendix 1.  
Adverse events were predefined as follows, taken directly from van der Gaag N, Rauws E, van 
Eijck C, Bruno M, van der Harst E, et al. Preoperative biliary drainage for cancer 
of the head of the pancreas. N Engl J Med 2010;362;129-37.  
• Acute pancreatitis:  Abdominal pain and a serum concentration of pancreatic enzymes 
(amylase or lipase) three or more times the upper limit of normal, that required more than 
one night of hospitalization 
• Acute cholecystitis:  No suggestive clinical or radiographic signs of acute cholecystitis 
before the procedure and if emergency cholecystectomy is subsequently required 
• Perforation:  Retroperitoneal or bowel-wall perforation documented by any radiographic 
technique or direct visual evidence  
• Stent Occlusion:  Recurring obstructive jaundice with necessary stent replacement  
• Pancreaticojejunostomy leakage:  Drain output of any measurable volume of fluid on or 
after postoperative day 3 with an amylase content greater than 3 times the serum amylase 
activity, graded according to clinical course (ISGPS grade A, B, C), or direct visual evidence 
of defect at anastomosis  
• Delayed gastric emptying:  Gastric stasis requiring nasogastric intubation for 10 days or 
more, or the inability to tolerate a regular (solid) diet on or before the fourteenth 
postoperative day, not due to sequelae of intra-abdominal complications (ie, abscess, 
anastomotic leakage)  
• Biliary leakage:  Bilirubin in abdominal drain or dehiscence found at laparotomy  
• Gastro/-duodenojejunostomy leakage:  Conclusive radiographic or direct visual evidence 
of a defect of the anastomosis  
• Intra-abdominal abscess formation:  Intra-abdominal fluid collection with positive cultures 
identified by ultrasonography or computed tomography, associated with persistent fever and 
elevations of white blood cells  
• Wound infection:  Requiring intervention otherwise considered as minor adverse event  
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• Portal Vein Thrombosis:  Conclusive radiologic evidence of thrombosis  
• Cholangitis:  Elevation in temperature more than 38°C, thought to have a biliary cause, 
without concomitant evidence of acute cholecystitis, requiring intervention  
• Hemorrhage:  Bleeding after the index procedure requiring transfusion of ≥4 units of 
packed cells within a 24-hour period, or leading to relaparotomy/intervention  
• (Emergency) (re)laparotomy:  Any (other) reason after either preoperative biliary drainage 
or another surgical procedure  
• Pneumonia:  Pulmonary infection with radiological confirmation and requiring antibiotic 
treatment  
• Mortality:  In-hospital death, due to protocol adverse events or any cause, including 
progression of disease, within the study period  
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Supplementary Figure 1.  
Kaplan-Meier analysis of primary endpoint in patients who underwent curative intent surgery 
in the intention-to-treat analysis set. 
Kaplan-Meier curves are shown for sustained biliary drainage, according to randomized 
treatment arm in an ITT analysis for the subset of patients who underwent CIS. Sustained biliary 
drainage occurred in 83.3% of patients with FCSEMS versus 84.1% of patients with UCSEMS at 
1 year (P = .97) in an analysis of N=51 patients who underwent CIS.    
Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered. 
 
Supplementary Figure 2.  
Kaplan-Meier analysis of primary endpoint in patients who did not undergo curative intent 
surgery in the intention-to-treat analysis set. 
Kaplan-Meier curves are shown for sustained biliary drainage, according to randomized 
treatment arm in an ITT analysis for the subset of patients who did not undergo CIS. Sustained 
biliary drainage occurred in 55.8% of patients with FCSEMS versus 47.0% of patients with 
UCSEMS at 1 year (P = .84) in an analysis of N=62 patients who did not undergo CIS.    
Abbreviations: CI, confidence interval; FC, fully covered; UC, uncovered. 
 
Supplementary Figure 3.  
Mean Bilirubin level as a function of follow-up visits  
Graph shows the mean Bilirubin level at 5 follow-up visits. Given that some patients underwent 
CIS and some did not, the number of patients per for whom the Bilirubin levels are documented 
varies per protocol at the various study visits. Specifically, the number of patients at each study 
visit in the graphic below is as follows: Baseline N=119, First preoperative visit N=111, Last 
pre-operative visit N=111, Transition to palliative management N=25, and One year after stent 
placement N=17.    
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Supplementary Table 1.  
Reinterventions 
Overall, 31 patients experienced an adverse event that required a reintervention during follow-up until CIS or 1 year if the patient 
could not undergo CIS. 
Symptom was categorized into “Cholangitis,” “Biliary obstruction,” which included biliary obstructive symptoms and/or abnormal 
liver function tests without cholangitis, and “Acute cholecystitis.” 
Cause was categorized into “Ingrowth” for tumor ingrowth into the SEMS, “Overgrowth” for hyperplastic or tumor overgrowth at the 
edges or extremity of the SEMS, “Migration” for partial distal or proximal migration or complete distal migration of the SEMS, 
“Presumed CD occlusion” reflecting the theoretical and presumed occlusion by the SEMS of the cystic duct confluence with the 
common bile duct, “Sludge,” which may have been further specified as sludge, necrotic debris, stones, or food impaction (causing 
succotash cholangitis in reintervention no. 26), “GI Bleed” in one case in setting of SEMS migration without biliary obstruction, and 
“Kinked SEMS” in one case of an UCSEMS having kinked after placement.   
Intervention is self-explanatory.  Second SEMS placed is applicable for reinterventions in which a SEMS is exchanged for another 
SEMS or in which a SEMS is placed inside of a SEMS.    
 
Reinter-
vention 
Number 
Group GB in Situ 
SEMS 
Length 
Days to 
reinter-
vention 
Days 
to CIS Cause Symptom Intervention 
Type of 
Stent 
Placed 
1 UC Yes 6 cm 195 NA Ingrowth Cholangitis Biliary RFA N/A 
2 UC Yes 6 cm 168 NA Ingrowth Cholangitis SEMS in SEMS FC 
3 UC Yes 6 cm 160 NA Ingrowth Cholangitis SEMS in SEMS FC 
4 UC Yes 6 cm 331 NA Ingrowth Cholangitis SEMS in SEMS FC 
5 UC Yes 6 cm 213 NA Ingrowth Cholangitis SEMS in SEMS FC 
6 UC Yes 4 cm 14 152 Ingrowth Biliary obstruction SEMS in SEMS FC 
7 UC Yes 4 cm 42 NA Ingrowth Biliary obstruction SEMS in SEMS FC 
8 UC Yes 4 cm 224 297 Ingrowth Biliary obstruction SEMS in SEMS UC 
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9 UC Yes 4 cm 227 NA Ingrowth Biliary obstruction SEMS in SEMS UC 
10 UC Yes 4 cm 73 83 Ingrowth Biliary obstruction PTBD N/A 
11 UC Yes 8 cm 38 60 
Presumed 
CD 
occlusion 
Acute cholecystitis Percutaneous 
cholecystostomy tube N/A 
12 UC Yes 4 cm 24 NA 
Presumed 
CD 
occlusion 
Acute cholecystitis Percutaneous 
cholecystostomy tube N/A 
13 UC Yes 4 cm 10 NA Sludge Cholangitis Sludge removal N/A 
14 UC Yes 4 cm 203 NA Overgrowth Biliary obstruction Plastic stent in SEMS N/A 
15 UC Yes 6 cm 7 NA Kinked SEMS Cholangitis SEMS in SEMS PC 
16 UC Yes 4 cm 17 22 
No observed 
SEMS 
occlusion or 
migration 
Cholangitis Naso-biliary drain N/A 
17 FC Yes 6 cm 140 NA Migration Cholangitis SEMS Exchange UC 
18 FC Yes 4 cm 88 NA Migration Cholangitis SEMS Exchange UC 
19 FC Yes 6 cm 13 63 Migration Cholangitis 
FCSEMS removal, 
non-study SEMS 
placed 
N/A 
20 FC Yes 6 cm 245 NA Migration Biliary obstruction 
FCSEMS removal, 
plastic or non-study 
SEMS placed 
N/A 
21 FC Yes 6 cm 204 NA Migration GI Bleed SEMS Exchange UC 
22 FC Yes 6 cm 7 110 
Presumed 
CD 
occlusion 
Acute cholecystitis Percutaneous 
cholecystostomy tube N/A 
23 FC Yes 4 cm 4 118 
Presumed 
CD 
occlusion 
Acute cholecystitis SEMS Exchange UC 
24 FC Yes 6 cm 53 NA Presumed Acute cholecystitis Percutaneous N/A 
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CD 
occlusion 
cholecystostomy tube 
25 FC Yes 6 cm 13 NA 
Presumed 
CD 
occlusion 
Acute cholecystitis Laparoscopic 
cholecystectomy N/A 
26 FC Yes 6 cm 22 NA Sludge Cholangitis SEMS Exchange UC 
27 FC No 6 cm 147 NA Sludge Cholangitis SEMS Exchange UC 
28 FC Yes 6 cm 168 NA Sludge Cholangitis FCSEMS removal, plastic stent placed N/A 
29 FC Yes 4 cm 204 NA Sludge Biliary obstruction SEMS Exchange UC 
30 FC Yes 4 cm 276 NA Overgrowth Biliary obstruction SEMS in SEMS UC 
31 FC Yes 4 cm 3 91 
No observed 
SEMS 
occlusion or 
migration 
Progressive Jaundice 
FCSEMS removal, 
naso-biliary drain and 
plastic stent placed 
N/A 
Abbreviations: CD, cystic duct; FC, fully-covered; UC, uncovered; GI, gastrointestinal; N/A, not applicable; RFA, radio frequency ablation; SEMS, self-
expanding metal stent; PC, partially covered; PTBD, percutaneous transhepatic biliary drain 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abbreviations: 
CIS - curative intent surgery  
CSEMS - covered self-expanding metal stents 
EUS FNA/FNB - endoscopic ultrasound fine needle aspiration or fine needle biopsy 
FCSEMS - fully-covered self-expanding metal stents  
ITT - intention-to-treat  
LFTs - liver function tests 
NATx - neoadjuvant therapy 
PD – pancreaticoduodenectomy 
PP - per protocol 
SEMS - self-expanding metal stents 
UCSEMS - uncovered self-expanding metal stents 
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Clinical Trial Registration: ClinicalTrials.gov NCT02238847 
 
